On 9 October 2025, the US Food and Drug Administration (FDA) approved Celltrion’s Eydenzelt (aflibercept-boav), a biosimilar referencing Regeneron’s Eylea (aflibercept). On 17October 2025, the FDA approved expanded indications for Celltrion’s Yuflyma (adalimumab-aaty) and its unbranded version.
Eydenzelt (aflibercept-boav), Celltrion's first FDA-approved biological product in ophthalmology, is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular oedema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR). The product has already been approved in the EU and Australia [1-3].
Eydenzelt is presented as a 2 mg (0.05 mL, 40 mg/mL) injection in a single-dose prefilled syringe (PFS) for intravitreal administration.
The FDA approval was based on a totality of evidence including analytical, nonclinical, and clinical evidence. A 52-week, phase III trial of 348 DME (diabetic macular oedema) patients compared Eydenzelt to Eylea. The primary endpoint of visual acuity change at week 8 met equivalence criteria. Secondary endpoints for efficacy, safety, and immunogenicity showed trends similar to Eylea.
Additionally, on 17 October 2025, the FDA approved expanded indications for Yuflyma (adalimumab-aaty) and its unbranded version, to include the treatment of hidradenitis suppurativa (HS) in adolescent patients aged 12 years and older, and uveitis (UV) in paediatric patients aged 2 years and older.
Celltrion’s Yuflyma was approved in the US in May 2023 and launched in July 2023. It is currently available as a 20 mg, 40 mg, and 80 mg solution for injection in PFS, and as a 40 mg and 80 mg solution in autoinjectors. Celltrion offers adalimumab-aaty in both branded and unbranded versions, with two pricing options to improve patient affordability and meet differing needs.
Related articles
FDA approves third aflibercept biosimilar Ahzantive
FDA approves adalimumab biosimilar Hadlima
FDA approval for Amgen’s adalimumab biosimilar
References
1. GaBI Online - Generics and Biosimilars Initiative. EC approves eight biosimilars, six more await final authorization [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Dec 5]. Available from: www.gabionline.net/biosimilars/news/ec-approves-eight-biosimilars-six-more-await-final-authorization
2. GaBI Online - Generics and Biosimilars Initiative. EMA recommends approval of three aflibercept biosimilars: Ahzantive, Baiama, and Eydenzelt [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Dec 5]. Available from: www.gabionline.net/biosimilars/news/ema-recommends-approval-of-three-aflibercept-biosimilars-ahzantive-baiama-and-eydenzelt
3. GaBI Online - Generics and Biosimilars Initiative. Australia biosimilar approvals in early 2025 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Dec 5]. Available from: www.gabionline.net/biosimilars/news/australia-biosimilar-approvals-in-early-2025
4. GaBI Online - Generics and Biosimilars Initiative. Celltrion: advances for Yuflyma and Vegzelma biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2025 Dec 5]. Available from: www.gabionline.net/biosimilars/news/celltrion-advances-for-yuflyma-and-vegzelma-biosimilars
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2025 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment